Aromatase inhibitors for endometriosis-related pain.

The pair was indexed against endometriosis through the Direct Research arm, which reads peer-reviewed literature and extracts a verbatim claim for each finding. The anchoring source is a systematic review of aromatase inhibitors for endometriosis-related pain, pooling seven studies including three randomized post-operative trials.

“AIs combined with either progestogens or oral contraceptive pill reduce the severity of pain symptoms”PubMed · PMID 21693038

Aromatase inhibitors suppress local and systemic estrogen production, reducing estrogen-dependent endometriotic lesion activity and associated pain.

Each dimension below carries the engine's own 0–2 score and the rationale it wrote. This is the live Direct-arm row, read straight from the substrate at request time.

This pair and the vaginal-estrogen pair share an identical corroboration score: both rest on a single ingested synthesis, so corroboration holds at 1 for each. The pooled studies inside a review do not count as independent sources. What separates them is consistency. Here the systematic review synthesises seven studies and three RCTs whose findings concordantly point the same way, so consistency scores 2. The vaginal-estrogen review offered a single figure with nothing to cross-check, so its consistency stayed at 1.

That one point is the whole difference between an 8.0 Strong and a 7.0 Moderate. It is also exactly the kind of distinction the rubric exists to make legible. The question it answers is how much the ingested evidence actually agrees with itself, and it leaves aside how famous the drug happens to be. See the companion case on the vaginal-estrogen page.

The clinical literature on aromatase inhibitors in endometriosis extends past the one review on file. The references below sit outside the ingested corpus today and are not folded into the score. They converge with the indexed signal and, if ingested, would raise its corroboration dimension.

A Strong tier records that the ingested evidence is high-design, specific to the intervention and condition, and internally consistent. It is a research lead that stops short of a clinical recommendation. The signal is indexed at the class level: anastrozole and letrozole are the specific agents behind it, and the score reflects the aromatase-inhibitor evidence the engine has read across the class, with no verdict on any one molecule.

Whel surfaces what the literature and underlying biology already imply and records how confident that inference is. It does not adjudicate clinical decisions.